Which glioblastoma patients will respond to immunotherapy? New biomarker discovery could prolong…
Northwestern Medicine scientists have discovered a new biomarker to identify which patients with brain tumors called glioblastomas -- the most common and malignant of primary brain tumors -- might benefit from immunotherapy.
The treatment…